SAAD Digest 

March 2025
Volume: 41
Issue: 1
DOI: 10.63507/QLKO2726

Title: A service evaluation of the use of IV sedation with remimazolam for adults with an acquired brain injury

Author(s):  M. Doshi, R. Prasad, D. Reilly. 

Abstract: 

Introduction
Remimazolam is an ultra-short-acting benzodiazepine that is an alternative to midazolam for dental sedation. Limited data exist on its use in dentistry for patients with medical complexities.

Methods
This study prospectively evaluated all patients receiving remimazolam for intravenous (IV) sedation by the Royal Hospital for Neuro-disability dental team over a period of six months.

Results
46 episodes of sedation with remimazolam were undertaken on 33 patients with an American Society of Anaesthesiologists (ASA) grade of 3. The mean dose of remimazolam was 11 mg. Total co-operation, with and without small amounts of uninvited movements, was documented to be 70%. The discharge time from the last dose of remimazolam ranged from 10-50 minutes. Four patients required supplemental oxygen or airway manoeuvres.

Conclusion
The data collected indicates that remimazolam may offer a safe and effective alternative to midazolam in this patient cohort.

To access this article please click here 
Please note: members will need to log on to access the article.

If you have a query relating to this article please email: contact@saad.org.uk

Articles from Digest 41(1)